| Name | Title | Contact Details |
|---|
SunLink Health Systems, Inc. currently operates seven community hospitals and related nursing home and home care businesses in the Southeast and Midwest, and its specialty pharmacy business, SunLink Scripts Rx, in Louisiana and Georgia. Each SunLink hospital is the only hospital in its community. SunLink's operating strategy is to link patients' needs with dedicated physicians and health professionals to deliver quality, efficient medical care and healthcare products and services in each area it serves. For additional information on SunLink Health Systems, Inc.
Sirius Medicine is a Loveland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alpha Source is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EyeCare Services Partners (ESP) provides ownership and practice management of ophthalmologic, optometric and ambulatory surgery centers nationwide. ESP offers eye care providers and ambulatory surgery center owners compelling and effective solutions for today`s constantly changing healthcare environment. Utilization of our resources and expertise eliminates the stress of practice management. We are creating the nation`s leading eyecare services company in both quality and scale by consolidating ophthalmologic and optometric practices and ambulatory surgery centers that are locally dominant and clinically differentiated. We provide a patient centric model that delivers outstanding care and quality outcomes through our providers and staff by leveraging our comprehensive array of best-in-class technology, processes and managerial infrastructure.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.